Clinical hematology international最新文献

英文中文

Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias – A Single Centre Experience. 单中心经验：亚洲浆细胞瘤患者对达拉单抗的耐受性

Q4 Health Professions

Clinical hematology international

Pub Date : 2024-01-16 DOI: 10.46989/001c.92085

A. Tso, S. Wang, C. Gallardo, D. Christopher, K. Ong

Daratumumab is increasingly incorporated into the standard treatment regimens for patients with plasma cell dyscrasias in Asia, especially with cost-containment measures implemented by various regional health authorities. This analysis aimed to study daratumumab’s tolerability amongst Asian patients. This is a retrospective medical records review of patients who received daratumumab between November 2016 and August 2021 as part of routine clinical care. Sixty-two patients were included in the study: 62.9% had renal impairment, and 27.4% had creatinine clearance (CrCl) <30ml/min. Forty-five patients (72.6%) received daratumumab combination therapy, with a median 1 line of prior therapy. The median duration of follow-up was 12.4 months, and the median duration patients were on treatment with daratumumab was 12.3 months. Twenty-one of 62 (33.9%) patients experienced infusion-related reactions (IRRs) after the first dose of intravenous daratumumab. Seven developed mostly grades 1 and 2 respiratory events, and 14 showed grades 1 and 2 non-respiratory IRRs. Only one patient experienced a grade 1 IRR with the second infusion, with none developing any IRRs in the third or subsequent infusions. Eight (12.9%) patients were affected by hematological adverse events (AEs), mostly grades 2 and 3, with one experiencing grade-4 neutropenia without sepsis. Six (9.7%) patients experienced non-hematological AEs, the commonest being pneumonia and other infections, with one developing Nocardia pneumonia (grade 4) 14 months after the initiation of daratumumab. In conclusion, daratumumab is tolerable amongst Asian patients, including the elderly, and patients with severe renal impairment and chronic lung diseases.

在亚洲，达拉单抗越来越多地被纳入血浆细胞异常患者的标准治疗方案，尤其是在各地区卫生当局实施成本控制措施的情况下。本分析旨在研究亚洲患者对达拉单抗的耐受性。这是一项回顾性病历审查，对象是2016年11月至2021年8月期间作为常规临床护理的一部分接受达拉单抗治疗的患者。研究共纳入62名患者：62.9%的患者存在肾功能损害，27.4%的患者肌酐清除率（CrCl）<30ml/min。45名患者（72.6%）接受了daratumumab联合疗法，中位数患者之前接受过一种疗法。中位随访时间为12.4个月，患者接受达拉单抗治疗的中位时间为12.3个月。62例患者中有21例（33.9%）在首次静脉注射达拉单抗后出现了输液相关反应（IRRs）。7名患者主要出现了1级和2级呼吸道反应，14名患者出现了1级和2级非呼吸道IRR。只有一名患者在第二次输注时出现了1级IRR，没有人在第三次或随后的输注中出现任何IRR。8名患者（12.9%）出现了血液学不良事件（AE），大部分为2级和3级，其中1名患者出现了4级中性粒细胞减少症，但无败血症。6名（9.7%）患者出现了非血液学不良事件，最常见的是肺炎和其他感染，其中1名患者在开始使用达拉单抗14个月后出现了诺卡菌肺炎（4级）。总之，亚洲患者（包括老年人、严重肾功能损害和慢性肺部疾病患者）可以耐受达拉单抗。

{"title":"Tolerability of Daratumumab Amongst Asian Patients with Plasma Cell Dyscrasias – A Single Centre Experience.","authors":"A. Tso, S. Wang, C. Gallardo, D. Christopher, K. Ong","doi":"10.46989/001c.92085","DOIUrl":"https://doi.org/10.46989/001c.92085","url":null,"abstract":"Daratumumab is increasingly incorporated into the standard treatment regimens for patients with plasma cell dyscrasias in Asia, especially with cost-containment measures implemented by various regional health authorities. This analysis aimed to study daratumumab’s tolerability amongst Asian patients. This is a retrospective medical records review of patients who received daratumumab between November 2016 and August 2021 as part of routine clinical care. Sixty-two patients were included in the study: 62.9% had renal impairment, and 27.4% had creatinine clearance (CrCl) <30ml/min. Forty-five patients (72.6%) received daratumumab combination therapy, with a median 1 line of prior therapy. The median duration of follow-up was 12.4 months, and the median duration patients were on treatment with daratumumab was 12.3 months. Twenty-one of 62 (33.9%) patients experienced infusion-related reactions (IRRs) after the first dose of intravenous daratumumab. Seven developed mostly grades 1 and 2 respiratory events, and 14 showed grades 1 and 2 non-respiratory IRRs. Only one patient experienced a grade 1 IRR with the second infusion, with none developing any IRRs in the third or subsequent infusions. Eight (12.9%) patients were affected by hematological adverse events (AEs), mostly grades 2 and 3, with one experiencing grade-4 neutropenia without sepsis. Six (9.7%) patients experienced non-hematological AEs, the commonest being pneumonia and other infections, with one developing Nocardia pneumonia (grade 4) 14 months after the initiation of daratumumab. In conclusion, daratumumab is tolerable amongst Asian patients, including the elderly, and patients with severe renal impairment and chronic lung diseases.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":" 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139618366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Are We Ready For "Triplet" Therapy in Higher-Risk MDS? 我们准备好接受高危MDS的“三联”治疗了吗？

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-11-03 eCollection Date: 2023-01-01 DOI: 10.46989/001c.88301

Andrew M Brunner, Uwe Platzbecker, Amy E DeZern, Amer M Zeidan

Higher-risk Myelodysplastic Syndromes/Neoplasms (MDS) represent an ongoing therapeutic challenge, with few effective therapies, many of which may have limited use in this older patient population often with considerations around comorbidities. Outside of transplant, azacitidine and decitabine remain the only disease-modifying therapies, and are palliative in nature. Recent interest has grown in extending combination chemotherapies used to treat acute myeloid leukemia (AML) to patients with MDS, including novel combination chemotherapy "doublets" and "triplets." In this review, we discuss considerations around combination chemotherapy in MDS, specifically as relates to study design, appropriate endpoints, supportive considerations, and how to integrate these into the current treatment paradigm. New therapies in MDS are desperately needed but also require considerations particular to this unique patient population.

高危骨髓增生异常综合征/肿瘤（MDS）是一个持续的治疗挑战，几乎没有有效的治疗方法，其中许多方法在老年患者群体中的应用可能有限，通常需要考虑合并症。除移植外，阿扎胞苷和地西他滨仍然是唯一的疾病改良疗法，本质上是姑息性的。最近，人们对将用于治疗急性髓细胞白血病（AML）的联合化疗扩展到MDS患者越来越感兴趣，包括新型联合化疗“双联”和“三联”。在这篇综述中，我们讨论了MDS联合化疗的考虑因素，特别是与研究设计、适当的终点、支持性考虑因素，以及如何将这些整合到当前的治疗模式中。MDS迫切需要新的治疗方法，但也需要特别考虑这一独特的患者群体。

引用次数: 0

Hottest topics in hematopoietic stem cell transplantation: a summary from the 8th International Transplant and Cellular Therapy Course. 造血干细胞移植最热门话题：第八届国际移植与细胞治疗课程综述。

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI: 10.46989/001c.89034

Edwin U Suárez

引用次数: 0

Walter Michael Kuehl, MD - October 25, 1939 - April 30, 2023 Walter Michael Kuehl，医学博士，1939年10月25日- 2023年4月30日

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-09-19 DOI: 10.46989/001c.87881

Leif Bergsagel

引用次数: 0

Standing on the Shoulders of the Giants: Dr. Alain Fischer. 站在巨人队的肩膀上：阿兰·菲舍尔博士。

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-09-16 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87882

Mohamad Mohty, Alain Fischer

Standing on the Shoulders of the Giants: Dr. Alain Fischer Mohamad Mohty , Alain Fischer 1 Sorbonne University, AP-HP, INSERM UMRs938, Paris, France, 2 Service d'Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, APHP, Paris, France, 3 Pediatric Hematology-Immunology and Rheumatology Department, Hôpital Necker-Enfants Malades, AP-HP Centre Université de Paris, Paris, France, 4 Institut Imagine, INSERM UMR 1163, Paris, France; Collège de France, Paris, France.

引用次数: 0

Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States. 美国住院患者浆细胞白血病结局的种族差异。

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-09-08 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87755

Cindy Wu, Deepa Dongarwar, Samer Al Hadidi

Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients' outcomes. In this study, we aimed to investigate racial differences in hospitalization outcomes for PCL using Nationwide Inpatient Sample data. Overall, hospitalization rates for PCL tended to decrease over the past decade. Among hospitalized patients with a primary diagnosis of PCL, there was no statistically significant association between race/ethnicity and hospitalization rates, between NH-White patients and NH-Black patients (OR 1.94; 95%CI 0.3-3.54, p 0.95), and Hispanic patients (OR 0.47; 95% CI 0.05-4.23, p 0.5). Additionally, there was no significant association between race/ethnicity and inpatient mortality. The overall lower incidence of PCL, more significant disease burden, and poor prognosis across all groups may contribute to our findings. With increasing evidence that PCL is cytogenetically distinct from MM, more investigation into biological and sociodemographic factors that affect healthcare utilization and treatment outcomes should be carried out.

浆细胞白血病（PCL）是一种罕见的侵袭性多发性骨髓瘤（MM）亚型，预后不良。先前的研究表明，种族差异以各种方式影响MM患者，这可能会影响患者的预后。在这项研究中，我们旨在使用全国住院患者样本数据调查PCL住院结果的种族差异。总体而言，PCL的住院率在过去十年中趋于下降。在主要诊断为PCL的住院患者中，种族/民族与住院率、NH白人患者和NH黑人患者（OR 1.94；95%CI 0.3-3.54，p 0.95）以及西班牙裔患者（OR 0.47；95%CI 0.05-4.23，p 0.5）之间没有统计学上的显著关联。此外，种族/民族与住院死亡率之间没有显著相关性。PCL的总体发病率较低，疾病负担更重，所有组的预后较差，这可能是我们的发现的原因。随着越来越多的证据表明PCL在细胞遗传学上与MM不同，应该对影响医疗利用和治疗结果的生物学和社会人口学因素进行更多的调查。

{"title":"Racial Disparities in Plasma Cell Leukemia Outcomes Among Hospitalized Patients in the United States.","authors":"Cindy Wu, Deepa Dongarwar, Samer Al Hadidi","doi":"10.46989/001c.87755","DOIUrl":"https://doi.org/10.46989/001c.87755","url":null,"abstract":"<p><p>Plasma cell leukemia (PCL) is a rare, aggressive subtype of multiple myeloma (MM) with a poor prognosis. Prior studies have shown that racial disparities affect MM patients in various ways, which may affect patients' outcomes. In this study, we aimed to investigate racial differences in hospitalization outcomes for PCL using Nationwide Inpatient Sample data. Overall, hospitalization rates for PCL tended to decrease over the past decade. Among hospitalized patients with a primary diagnosis of PCL, there was no statistically significant association between race/ethnicity and hospitalization rates, between NH-White patients and NH-Black patients (OR 1.94; 95%CI 0.3-3.54, p 0.95), and Hispanic patients (OR 0.47; 95% CI 0.05-4.23, p 0.5). Additionally, there was no significant association between race/ethnicity and inpatient mortality. The overall lower incidence of PCL, more significant disease burden, and poor prognosis across all groups may contribute to our findings. With increasing evidence that PCL is cytogenetically distinct from MM, more investigation into biological and sociodemographic factors that affect healthcare utilization and treatment outcomes should be carried out.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"5 4","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2023-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/20/chi_2023_5_4_87755.PMC10515655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41168866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Incorporation of Ruxolitinib in the Management of Refractory/Relapsed Hodgkin Lymphoma: Where Do We Stand? Ruxolitinib在难治性/复发性霍奇金淋巴瘤治疗中的应用：我们的立场？

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-08-28 eCollection Date: 2023-01-01 DOI: 10.46989/001c.87501

Ahmed H Al Sharie, Balqis M Abu Mousa, Ahmad O Alomari

引用次数: 0

Racial Differences in Spinal Cord Compression Related Hospitalizations in Patients with Multiple Myeloma 多发性骨髓瘤患者脊髓压迫相关住院治疗的种族差异

Q4 Health Professions

Clinical hematology international

Pub Date : 2023-02-03 DOI: 10.46989/001c.87569

Samer Al Hadidi, Deepa Dongarwar, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, John D. Shaughnessy, Frits van Rhee

By Samer Al Hadidi, Deepa Dongarwar & 5 more. Non-Hispanic (NH) Black and Hispanic persons with multiple myeloma (MM) face multiple health-related disparities that include lower access to novel therapies and under-utilization of autologous stem cell transplantation.

作者:Samer Al Hadidi, Deepa Dongarwar等。非西班牙裔(NH)黑人和西班牙裔多发性骨髓瘤(MM)患者面临多种与健康相关的差异，包括获得新疗法的机会较低和自体干细胞移植的利用不足。

引用次数: 0

Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation 造血干细胞移植后单核细胞重建和肠道菌群组成

Q4 Health Professions

Clinical hematology international

Pub Date : 2019-09-20 DOI: 10.1101/777268

S. Morjaria, Allen W. Zhang, Sohn G. Kim, J. Peled, Simone Becattini, E. Littmann, E. Pamer, M. Perales, Michael C. Abt

Monocytes are an essential cellular component of the innate immune system that support the host’s effectivenss to combat a range of infectious pathogens. Hemopoietic cell transplantation (HCT) results in transient monocyte depletion, but the factors that regulate recovery of monocyte populations are not fully understood. In this study, we investigated whether the composition of the gastrointestinal microbiota is associated with the recovery of monocyte homeostasis after HCT. Methods We performed a single-center, prospective, pilot study of 18 recipients of either autologous or allogeneic HCT. Serial blood and stool samples were collected from each patient during their HCT hospitalization. Analysis of the gut microbiota was done using 16S rRNA gene sequencing and flow cytometric analysis was used to characterize the phenotypic composition of monocyte populations. Results Dynamic fluctuations in monocyte reconstitution occurred after HCT and large differences were observed in monocyte frequency among patients over time. Recovery of absolute monocyte counts and monocyte subsets showed significant variability across the heterogeneous transplant types and conditioning intensities; no relationship to the microbiota composition was observed in this small cohort. Conclusion A relationship between the microbiota composition and monocyte homeostasis could not be firmly established in this pilot study.

单核细胞是先天免疫系统的重要细胞组成部分，支持宿主有效地对抗一系列传染性病原体。造血细胞移植(HCT)导致短暂的单核细胞耗竭，但调节单核细胞群恢复的因素尚不完全清楚。在这项研究中，我们研究了胃肠道微生物群的组成是否与HCT后单核细胞稳态的恢复有关。方法:我们对18名自体或异体HCT接受者进行了一项单中心、前瞻性、先导研究。在每位患者的HCT住院期间收集了连续的血液和粪便样本。使用16S rRNA基因测序对肠道微生物群进行分析，并使用流式细胞分析表征单核细胞群体的表型组成。结果HCT后单核细胞重构出现动态波动，不同患者单核细胞频率随时间变化差异较大。绝对单核细胞计数和单核细胞亚群的恢复在不同的移植类型和调节强度中显示出显著的差异;在这个小队列中没有观察到与微生物群组成的关系。结论在本初步研究中，微生物群组成与单核细胞稳态之间的关系尚不能确定。

{"title":"Monocyte Reconstitution and Gut Microbiota Composition after Hematopoietic Stem Cell Transplantation","authors":"S. Morjaria, Allen W. Zhang, Sohn G. Kim, J. Peled, Simone Becattini, E. Littmann, E. Pamer, M. Perales, Michael C. Abt","doi":"10.1101/777268","DOIUrl":"https://doi.org/10.1101/777268","url":null,"abstract":"Monocytes are an essential cellular component of the innate immune system that support the host’s effectivenss to combat a range of infectious pathogens. Hemopoietic cell transplantation (HCT) results in transient monocyte depletion, but the factors that regulate recovery of monocyte populations are not fully understood. In this study, we investigated whether the composition of the gastrointestinal microbiota is associated with the recovery of monocyte homeostasis after HCT. Methods We performed a single-center, prospective, pilot study of 18 recipients of either autologous or allogeneic HCT. Serial blood and stool samples were collected from each patient during their HCT hospitalization. Analysis of the gut microbiota was done using 16S rRNA gene sequencing and flow cytometric analysis was used to characterize the phenotypic composition of monocyte populations. Results Dynamic fluctuations in monocyte reconstitution occurred after HCT and large differences were observed in monocyte frequency among patients over time. Recovery of absolute monocyte counts and monocyte subsets showed significant variability across the heterogeneous transplant types and conditioning intensities; no relationship to the microbiota composition was observed in this small cohort. Conclusion A relationship between the microbiota composition and monocyte homeostasis could not be firmly established in this pilot study.","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"4 1","pages":"156 - 164"},"PeriodicalIF":0.0,"publicationDate":"2019-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73184002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 5

首页上一页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Clinical hematology international

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀